OmniCAR is a next-generation CAR-T platform that utilises a novel covalent binding system that aims to address several common challenges to the CAR-T field. OmniCAR can be armed with different binders to create multivalent CAR-T cells to address antigen heterogeneity. OmniCAR can be used as a pre-armed product or infused OmniCAR T cells re-armed through the addition of new binders. These features have significant implications on manufacturing processes, cost of goods and time to treatment. This is particularly true in the setting of antigen escape and/or antigen heterogeneity as the redirection of conventional CAR-T typically relies on re-starting the manufacturing process from backup lots or requiring the patient to undergo further rounds of apheresis. Exciting new data will be presented demonstrating some of the key attributes of OmniCAR and their implications on manufacturing cellular immuno-oncology products. Prescient has committed to developing OmniCAR for acute myeloid leukaemia, solid cancers (gastric, ovarian and breast) and glioblastoma multiforme.